pharma is the sole category represented across all 1 tracked stories. Danish Medicines Agency is most often covered alongside Depo-Provera, which appears in 1 of these 1 story. Source depth averages 3 original sources per story, versus 2.5 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Danish Medicines Agency
pharma is the sole category represented across all 1 tracked stories. Danish Medicines Agency is most often covered alongside Depo-Provera, which appears in 1 of these 1 story. Source depth averages 3 original sources per story, versus 2.5 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 5.7. Danish Medicines Agency appears in 1 tracked Biotech story from August 1, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Danish Medicines Agency. Shared-story counts are live from our verified record — not editorial picks.
The Danish Medicines Agency’s real-world evidence analysis implicates drospirenone, desogestrel, gestodene, and others in meningioma development, reshaping the risk-benefit landscape for pharmaceutical manufacturers and future contraceptive R&D.